ArticlePloS one2025
Potential role of miR-29b from mesenchymal stromal cell-derived extracellular vesicles in leukemic cell progression.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating extracellular vesicle-microRNAs (EV-miRNAs) in leukemias and related disorders.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crosstalk between leukemic cells and their surrounding mesenchymal stromal cells (MSCs) in the bone marrow microenvironment is crucial for the pathogenesis of myelodysplastic syndromes (MDS) and is mediated by extracellular vesicles (EVs). The EV-specific miRNAs derived from MDS-MSCs remain poorly explored. EVs isolated from HS-5, an immortalized stromal cell line, promoted the proliferation and 5-azacytidine (AZA) resistance of SKM-1 cells. EVs from MDS-MSCs and HS-5 cells showed significantly higher miRNA-29b-3p but lower let-7a-5p and miR-23-3p compared to healthy controls. miR-29b was selected for further investigation because it negatively regulates epigenetic modifier genes such as DNMTs and TETs, mutations of which are common in MDS. When we transduced miR-29b into leukemic cells, these cells demonstrated greater resistance to AZA and venetoclax than did their parental cells, mirroring the effect observed with HS-5 EVs. The introduction of miR-29b down-regulated DNMT1, DNMT3L, TET1, and TET2, which may underlie the changes in DNA methylation levels, increased chromosomal instability, activation of type I interferon pathways, acquired cell migration, and drug resistance observed in leukemic cells. Overall, we suggest that the sustained influx of miR-29b through EVs may catalyze the evolution of leukemic cells, and its clinical relevance warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.